Disclsoed herein are indazole compounds of formula I where the substituents are as defined herein. The compounds are intended for use in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer&rsquos disease, lung disease and osteoarthritis). The disclosure particularly relates to the compound: N-(5-(3-(7-(3-fluoropheny1)-3H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-5-yl)pyridin-3-y1)-3-methylbutanamide. Other examples of the compounds of formula I include: 4-(2-(5-(pyridin-3-yl)-1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridin-7-yl)morpholine and N-(5-(3-(3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)isobutyramide.
